INTI
Inhibitor Therapeutics, Inc.
Price Chart
Latest Quote
$0.08
+0.00 (+0.00%)
Current Price
| Previous Close | $0.08 |
| Open | $0.08 |
| Day High | $0.08 |
| Day Low | $0.08 |
| Volume | 200 |
Stock Information
| Shares Outstanding | 172.57M |
| Total Debt | $58K |
| Cash Equivalents | $1.29M |
| Net Income | $-3.35M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $13.29M |
| EPS (TTM) | $-0.02 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $12.06M |
| Income | $-3.35M |
| Book/sh | $-0.01 |
| Cash/sh | $0.01 |
| Employees | 2 |
Financial Ratios
| Quick Ratio | 3.38 |
| Current Ratio | 3.60 |
Returns & Margins
| ROA | -72.57% |
Ownership
| Insider Ownership | 57.13% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -11.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.08 |
| SMA50 | $0.08 |
| SMA200 | $0.07 |
| RSI | 34.78 |
| ATR | 0.0020 |
| Shares Float | 77.66M |
| Short Float | 0.36% |
| Short Ratio | 0.08 |
| Volatility | -0.80 |
Performance History
| Week | -9.41% |
| Month | -2.53% |
| Quarter | -11.49% |
| 6 Months | +71.11% |
| YTD | +63.83% |
| Year | +79.07% |
| 3 Years | +120.00% |
| 5 Years | -46.90% |
| 10 Years | -69.32% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.08 | 0 |
| 2026-06-23 | $0.08 | 19,500 |
| 2026-06-22 | $0.09 | 0 |
| 2026-06-18 | $0.09 | 0 |
| 2026-06-17 | $0.09 | 0 |
| 2026-06-16 | $0.09 | 0 |
| 2026-06-15 | $0.09 | 0 |
| 2026-06-12 | $0.09 | 0 |
| 2026-06-11 | $0.09 | 0 |
| 2026-06-10 | $0.09 | 0 |
| 2026-06-09 | $0.09 | 0 |
| 2026-06-08 | $0.09 | 15,000 |
| 2026-06-05 | $0.08 | 22,600 |
| 2026-06-04 | $0.08 | 0 |
| 2026-06-03 | $0.08 | 0 |
| 2026-06-02 | $0.08 | 1,200 |
| 2026-06-01 | $0.09 | 0 |
| 2026-05-29 | $0.09 | 0 |
| 2026-05-28 | $0.09 | 0 |
| 2026-05-27 | $0.09 | 17,900 |
| 2026-05-26 | $0.08 | 1,500 |
About Inhibitor Therapeutics, Inc.
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. The company was founded in 1992 and is based in Tampa, Florida.
đ° Latest News
No news articles available at the moment. Check back later for updates on INTI.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $3,657,409 | $3,404,979 | $657,926 | $325,395 |
| Net Non Operating Interest Income Expense | $318,208 | $378,844 | $-23,234 | $-14,837 |
| Operating Expense | $3,657,409 | $3,404,979 | $657,926 | $325,395 |
| General And Administrative Expense | $1,974,859 | $2,023,913 | $651,776 | $320,490 |
| Interest Expense | - | $0 | $23,234 | $14,837 |
| Interest Expense Non Operating | - | $0 | $23,234 | $14,837 |
| Other Income Expense | - | - | $12,842,499 | $41,600 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,339,201 | $-3,026,135 | $12,106,230 | $-298,632 |
| Net Interest Income | $318,208 | $378,844 | $-23,234 | $-14,837 |
| Interest Income | $318,208 | $378,844 | $0 | - |
| Normalized Income | $-3,339,201 | $-3,026,135 | $-678,073 | $-340,232 |
| Net Income From Continuing And Discontinued Operation | $-3,339,201 | $-3,026,135 | $12,106,230 | $-298,632 |
| Total Operating Income As Reported | $-3,657,409 | $-3,404,979 | $-657,926 | $-325,395 |
| Net Income Common Stockholders | $-3,339,201 | $-3,026,135 | $11,917,188 | $-498,633 |
| Net Income | $-3,339,201 | $-3,026,135 | $12,106,230 | $-298,632 |
| Net Income Including Noncontrolling Interests | $-3,339,201 | $-3,026,135 | $12,106,230 | $-298,632 |
| Net Income Continuous Operations | $-3,339,201 | $-3,026,135 | $12,106,230 | $-298,632 |
| Pretax Income | $-3,339,201 | $-3,026,135 | $12,161,339 | $-298,632 |
| Interest Income Non Operating | $318,208 | $378,844 | $0 | - |
| Operating Income | $-3,657,409 | $-3,404,979 | $-657,926 | $-325,395 |
| Special Income Charges | - | $0 | $12,842,499 | $41,600 |
| Per Share | ||||
| Diluted EPS | $-0.02 | $-0.02 | $0.03 | $-0.00 |
| Basic EPS | $-0.02 | $-0.02 | $0.03 | $-0.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $58,196 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,657,409 | $-3,404,979 | $-657,926 | $-325,395 |
| EBITDA (Bullshit earnings) | $-3,657,409 | $-3,404,979 | $12,184,573 | $-283,795 |
| EBIT | $-3,657,409 | $-3,404,979 | $12,184,573 | $-283,795 |
| Diluted Average Shares | $172,262,889 | $171,950,108 | $366,183,697 | $376,247,777 |
| Basic Average Shares | $172,262,889 | $171,950,108 | $366,183,697 | $376,247,777 |
| Diluted NI Availto Com Stockholders | $-3,339,201 | $-3,026,135 | $11,917,188 | $-498,633 |
| Research And Development | $1,682,550 | $1,381,066 | $6,150 | $4,905 |
| Selling General And Administration | $1,974,859 | $2,023,913 | $651,776 | $320,490 |
| Other Gand A | $1,974,859 | $2,023,913 | $651,776 | $320,490 |
| Total Unusual Items | - | $0 | $12,842,499 | $41,600 |
| Total Unusual Items Excluding Goodwill | - | $0 | $12,842,499 | $41,600 |
| Tax Provision | - | $0 | $55,109 | $0 |
| Preferred Stock Dividends | - | - | $189,042 | $200,001 |
| Other Special Charges | - | - | $-12,842,499 | $-41,600 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,985,040 | $5,283,991 | $8,296,342 | $-3,620,846 |
| Total Assets | $5,694,658 | $8,949,155 | $11,975,124 | $58,784 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $5,694,658 | $8,949,155 | $11,975,124 | $58,784 |
| Other Current Assets | $87,795 | $109,243 | $23,900 | - |
| Cash Cash Equivalents And Short Term Investments | $5,606,863 | $8,839,912 | $11,951,224 | $30,626 |
| Cash And Cash Equivalents | $5,606,863 | $8,839,912 | $11,951,224 | $30,626 |
| Prepaid Assets | - | - | $23,900 | $28,158 |
| Debt | ||||
| Total Debt | - | - | $411,000 | $231,000 |
| Current Debt And Capital Lease Obligation | - | - | $411,000 | $231,000 |
| Current Debt | - | - | $411,000 | $231,000 |
| Other Current Borrowings | - | - | $411,000 | $231,000 |
| Net Debt | - | - | - | $200,374 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,709,618 | $3,665,164 | $3,678,782 | $3,679,630 |
| Total Non Current Liabilities Net Minority Interest | $3,000,000 | $3,000,000 | $3,000,000 | $3,000,000 |
| Non Current Deferred Liabilities | $3,000,000 | $3,000,000 | $3,000,000 | $3,000,000 |
| Current Liabilities | $709,618 | $665,164 | $678,782 | $679,630 |
| Payables And Accrued Expenses | $709,618 | $665,164 | $267,782 | $448,630 |
| Payables | $15,896 | $33,731 | $145,161 | $380,665 |
| Accounts Payable | $15,896 | $33,731 | $145,161 | $279,842 |
| Current Notes Payable | - | $0 | $411,000 | - |
| Other Current Liabilities | - | - | $122,621 | $53,000 |
| Interest Payable | - | - | $0 | $14,965 |
| Dividends Payable | - | - | $0 | $100,823 |
| Equity | ||||
| Common Stock Equity | $1,985,040 | $5,283,991 | $8,296,342 | $-7,581,712 |
| Total Equity Gross Minority Interest | $1,985,040 | $5,283,991 | $8,296,342 | $-3,620,846 |
| Stockholders Equity | $1,985,040 | $5,283,991 | $8,296,342 | $-3,620,846 |
| Retained Earnings | $-52,119,257 | $-48,780,056 | $-45,753,921 | $-57,671,109 |
| Preferred Stock Equity | - | - | - | $3,960,866 |
| Other | ||||
| Ordinary Shares Number | $172,323,545 | $172,023,545 | $171,793,134 | $376,858,323 |
| Share Issued | $172,323,545 | $172,023,545 | $171,793,134 | $376,858,323 |
| Tangible Book Value | $1,985,040 | $5,283,991 | $8,296,342 | $-7,581,712 |
| Invested Capital | $1,985,040 | $5,283,991 | $8,707,342 | $-7,350,712 |
| Working Capital | $4,985,040 | $8,283,991 | $11,296,342 | $-620,846 |
| Total Capitalization | $1,985,040 | $5,283,991 | $8,296,342 | $-3,620,846 |
| Additional Paid In Capital | $54,087,065 | $54,046,845 | $54,033,084 | $50,051,711 |
| Capital Stock | $17,232 | $17,202 | $17,179 | $3,998,552 |
| Common Stock | $17,232 | $17,202 | $17,179 | $37,686 |
| Preferred Stock | $0 | $0 | $0 | $3,960,866 |
| Non Current Deferred Revenue | $3,000,000 | $3,000,000 | $3,000,000 | $3,000,000 |
| Current Accrued Expenses | $693,722 | $631,433 | $122,621 | $67,965 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-3,233,049 | $-2,700,312 | $11,740,598 | $-220,433 |
| Operating Activities | ||||
| Operating Cash Flow | $-3,233,049 | $-2,700,312 | $11,740,598 | $-220,433 |
| Cash Flow From Continuing Operating Activities | $-3,233,049 | $-2,700,312 | $11,740,598 | $-220,433 |
| Operating Gains Losses | - | - | - | $-41,600 |
| Financing Activities | ||||
| Financing Cash Flow | $0 | $-411,000 | $180,000 | $176,000 |
| Cash Flow From Continuing Financing Activities | $0 | $-411,000 | $180,000 | $176,000 |
| Other | ||||
| Repayment Of Debt | $0 | $-411,000 | $0 | - |
| Income Tax Paid Supplemental Data | $0 | $53,088 | $0 | - |
| End Cash Position | $5,606,863 | $8,839,912 | $11,951,224 | $30,626 |
| Beginning Cash Position | $8,839,912 | $11,951,224 | $30,626 | $75,059 |
| Changes In Cash | $-3,233,049 | $-3,111,312 | $11,920,598 | $-44,433 |
| Net Issuance Payments Of Debt | $0 | $-411,000 | $180,000 | $176,000 |
| Net Short Term Debt Issuance | $0 | $-411,000 | $180,000 | - |
| Short Term Debt Payments | $0 | $-411,000 | $0 | - |
| Change In Working Capital | $65,902 | $312,039 | $142,087 | $81,809 |
| Change In Payables And Accrued Expense | $44,454 | $397,382 | $137,829 | $53,267 |
| Change In Payable | $44,454 | $397,382 | $137,829 | $53,267 |
| Change In Account Payable | $44,454 | $397,382 | $137,829 | $53,267 |
| Change In Prepaid Assets | $21,448 | $-85,343 | $4,258 | $28,542 |
| Stock Based Compensation | $40,250 | $13,784 | $0 | $37,990 |
| Net Income From Continuing Operations | $-3,339,201 | $-3,026,135 | $12,106,230 | $-298,632 |
| Issuance Of Debt | - | $0 | $180,000 | $176,000 |
| Short Term Debt Issuance | - | $0 | $180,000 | - |
| Net Long Term Debt Issuance | - | $-411,000 | $180,000 | $176,000 |
| Long Term Debt Payments | - | $-411,000 | $0 | - |
| Long Term Debt Issuance | - | $0 | $180,000 | $176,000 |
| Other Non Cash Items | - | - | $-507,719 | $-41,600 |
Fetched: 2026-02-02